In 2012, the MHRA recommended that oral tacrolimus products should be prescribed and dispensed by brand name only, to ensure maintenance of therapeutic response when a patient is stabilised on a particular brand. If a prescriber considers that switching a patient to a different brand of oral tacrolimus would be of benefit, the change requires careful supervision and therapeutic monitoring by an appropriate specialist.